HuMax-IL8

HuMax®-IL8 is a high affinity fully human antibody directed towards IL-8. IL-8 has been shown to be involved in several aspects of tumor development, including tumor spread (metastasis), cancer stem cell renewal and tumor immunosuppression. HuMax-IL8 has been shown to inhibit these processes and to inhibit tumor growth in pre-clinical tumor models. HuMax-IL8 is in development for the treatment of solid tumors under an agreement with Bristol-Myers Squibb. An IND for a Phase Ib study of HuMax-IL8 for the treatment of metastatic solid tumors was filed in June 2015.

Back to top

Metastatic solid tumors are formed by cancer cells that have spread from the original, primary, cancer, to other parts of the body. Almost all cancers, including blood cancers and those originating in the lymphatic system such as leukemia, multiple myeloma and lymphoma, can form metastatic tumors. The most common locations for cancer metastasis are in the bone, the liver and the lungs. Most metastatic cancer cannot be cured with current treatments.




Back to top